Ask AI
ProCE Banner Activity

Are You Keeping Up in IBD? Experts Answer Your Frequently Asked Questions

Clinical Thought

Treatment decisions in inflammatory bowel disease increasingly require APPs to integrate objective measures of inflammation, patient symptoms, treatment response, access barriers, and care-team collaboration. This ClinicalThought explores practice-relevant questions about de-escalation, treatment switching, and optimization of advanced therapies, including how biomarkers, endoscopy, therapeutic drug monitoring, insurance challenges, and specialist collaboration can inform clinical decision-making. Learners will consider how evidence-based, tight-control strategies can help reduce risks associated with uncontrolled inflammation and unnecessary corticosteroid exposure while supporting individualized, multidisciplinary IBD care.

Released: July 16, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options LLC dba Decera Clinical Education in partnership with the American Gastroenterological Association.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

American Gastroenterological Association

ProCE Banner

Target Audience

This educational activity is intended for gastroenterology nurse practitioners and physician associates, other advanced practice providers, such as those practicing in primary care, who are engaged in the care of patients with IBD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply expert consensus guidance to treatment monitoring and treatment advancement decisions for patients with IBD

Financial Disclosures

Primary Author

Jordan E. Axelrad, MD, MPH, AGAF, FACG, FCCF: researcher: Genentech, Johnson & Johnson, Takeda; consultant/advisor/speaker: AbbVie, Abivax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Johnson & Johnson, Lilly, Merck, Sanofi, Pfizer, Takeda, Vedanta.

Jami Kinnucan, MD, AGAF, FACG, FCCF: consultant/advisor/speaker: AbbVie, Johnson & Johnson, Lilly, Pfizer, Takeda.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.